Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

CUSIP: 59045L106

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
-16,798,108
Put/Call ratio
80%
SEC-reported price per share
$0.34
Number of holders
109
Value change
-$35,777,339
Number of buys
51
Open additional details 1 more signal available
Number of sells
80
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
4,992,318

Security key

59045L106

Report period

Q1 2025

Institutions

109

Top holders

10

Ownership snapshot

Top reported holders of MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Nextech Crossover I GP S....
Disclosed value leader
Crossover I. Scsp Nextech
Comparable rows
3/15
Latest evidence
31 Mar 2025
13D/G 13F 3/4/5 Lead comparable stake: 10% 12 rows are not safely comparable across share classes. 13D/G row: Nextech Crossover I GP S.a r.l. Showing 1-6 of 15 holder rows.

Quick read

Nextech Crossover I GP S.a r.l. leads the comparable SEC ownership view at 10%.

3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Nextech Crossover I GP S.a r.l.'s linked filing trail.
Comparable ownership Top 3
Nextech Crossover I GP S.a r.l. 10%
VANGUARD GROUP INC 6.7%
Venrock Healthcare Capital Partne... 2.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Nextech Crossover I GP S.a r.l.
13D/G
10%
Reported 13D/G · 20 Dec 2024
$4,344,209
12,067,246 shares
$0 20 Dec 2024
VANGUARD GROUP INC
13F 13D/G
Company · The Vanguard Group
6.7%
Reported 13D/G · 31 Mar 2025
$10,092,247
7,057,516 shares
— 31 Dec 2024
Venrock Healthcare Capital Partners III, L.P.
13D/G
2.9%
Reported 13D/G · 31 Mar 2025
$1,286,757
3,574,325 shares
-$2,406,047 31 Mar 2025
Crossover I. Scsp Nextech
3/4/5
10%+ Owner
—
denominator unverified
$22,927,767
12,067,246 shares
— 20 Dec 2024
EcoR1 Capital, LLC
3/4/5 13F
10%+ Owner · Company
—
mixed-class rows
$21,523,200
19,364,688 shares
mixed-class rows
— 19 Dec 2024
Nextech Invest Ltd.
13F
Company
13F
—
denominator unverified
$17,256,162
12,067,246 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
109
Shares
87,949,584
Rows available
109
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q4 2025 Across Filers

Q4 2025 holders
3
Q1 2025 holders
109
Holder diff
106
Investor Q4 2025 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2025 value Q1 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .